Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

AAD 2024 Insights: Immunomodulators in Non-Melanoma Skin Cancer

AAD 2024

V. Patel

Year in Review: Updates in Non-Melanoma Skin Cancers

Dana-Farber Cancer Institute

K. Khaddour

EADV 2023 Insights: Non-Melanoma Skin Cancer Management in Organ Tra…

EADV 2023 Insights

G. Hofbauer

EADV 2024 Insights: Dermatology in Skin of Color Patients - Challeng…

EADV 2024 Insights

N. Benmehidi

ESMO 2023 Insights: "Neoadjuvant Cemiplimab for Stage II to IV CSCC …

Insights from 2023 ESMO Annual Meeting

N. Gross

Updates in non-Melanoma Skin Cancer

Head and Neck Symposium: Skin Malignancies Update

S. Daveluy

Neoadjuvant IO: Non-Melanoma Skin Cancer

ImmunoTherapy Bridge 2023

N. Gross

Fred Hutchinson Cancer Center Head & Neck Cancer Updates

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

C. Rodriguez

Non-Melanoma Skin Cancers

ImmunoTherapy Bridge 2023

P. A. Ascierto

2023 ASCO® Direct Philadelphia: Melanoma Updates

Total Health

M. Orloff

PD-1 Inhibitors for Advanced Basal Cell Carcinoma and Squamous Cell …

Todd Schlesinger

ASCO® 2023 Insights: "To Treat or Not to Treat - Challenging Scenari…

Insights from 2023 ASCO® Annual Meeting

K. Margolin

ESMO 2023 Insights: "Survival Results for Neoadjuvant Cemiplimab in …

ecancer

N. Gross

Clinical Activity of MCLA-158 (Petosemtamab), an IgG1 Bispecific Ant…

AACR 2023 Conference Coverage

E. Cohen

Immunotherapy and Anti-Angiogenic Therapies in HNSCC

Yale Cancer Center

A. Bhatia

Harnessing IO in the Management of CSCC

Winship Cancer Institute - Emory University

N. Saba

Update on HPV Testing in Head and Neck Cancer

Houston Methodist

M. R. Schwartz

Best of SITC 2023 for Clinical Development and IO Trials

ImmunoTherapy Bridge 2023

P. A. Ascierto